Why the study?
What is the long-term risk of cardiac abnormalities in childhood survivors of solid tumours treated with adriamycin?
Population
229 childhood survivors of a solid tumour evaluated 15 years or more after adriamycin therapy
Design
Cohort
Follow-up
average 18 years
Authors
Loading...
Long-term cardiac surveillance may be warranted in survivors; leaves open optimal screening and prevention strategies.
What is the long-term risk of cardiac abnormalities in childhood survivors of solid tumours treated with adriamycin?
Childhood survivors of solid tumors treated with adriamycin face a high, dose-dependent risk of severe cardiac dysfunction and heart failure even 15 or more years after treatment.
Pein et al. (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: